Home › NDC Lookup › RxCUI directory › RxCUI 2602117

Edaravone 21 MG/ML Oral Suspension — RxCUI 2602117

RxNorm drug concept · Semantic clinical drug
RxCUI 2602117 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2602117
Official nameEdaravone 21 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asedaravone 735 MG per 35 ML Oral Suspension; edaravone 1050 MG per 50 ML Oral Suspension
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)705 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Edaravone Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Radicava is approved to treat ALS — amyotrophic lateral sclerosis, sometimes called Lou Gehrig's disease. It's a progressive condition that damages the nerve cells that control you...
  • Radicava is given as an IV infusion, which means it goes directly into a vein through a drip over about 60 minutes. A healthcare professional administers each dose. It follows a cy...
  • How is this medication given — do I take it at home?
  • The most common ones seen in studies were bruising, trouble walking, and headache. Skin reactions like rash or eczema were also reported. The most serious concern is a severe aller...
📖 Read our full Edaravone Injection guide →

🕸️ Concept Web — How Edaravone 21 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Edaravone 21 MG/ML Oral Suspension RxCUI 2602117

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Edaravone 1921877
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Radicava 1921882
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Edaravone Oral Suspension 2602116
    • Edaravone Oral Liquid Product 2602115
    • Edaravone Oral Product 2602114
    • Edaravone Oral Suspension [Radicava] 2602121
    • Radicava Oral Liquid Product 2602120
    • Radicava Oral Product 2602119
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Edaravone 21 MG/ML SCDC · 2602113
  • Edaravone Oral Suspension SCDF · 2602116
  • Edaravone Oral Liquid Product SCDG · 2602115
  • Edaravone Oral Product SCDG · 2602114

Brand-Name Concepts

  • Edaravone 21 MG/ML Oral Suspension [Radicava] SBD · 2602122
  • Edaravone 21 MG/ML [Radicava] SBDC · 2602118
  • Edaravone Oral Suspension [Radicava] SBDF · 2602121
  • Radicava Oral Liquid Product SBDG · 2602120
  • Radicava Oral Product SBDG · 2602119
  • Radicava BN · 1921882

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2602117 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70510-2321-02 2 CARTON in 1 CARTON (70510-2321-2) / 1 KIT in 1 CARTON (70... RADICAVA ORS Shionogi Inc. 2022-05-12
70510-2322-01 1 KIT in 1 CARTON (70510-2322-1) * 50 mL in 1 BOTTLE (7051... RADICAVA ORS Shionogi Inc. 2022-05-12
Observed labelers: Shionogi Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.